NCT04715165

Brief Summary

Pain after laparoscopic cholecystectomy is common and may lead to delayed hospital discharge.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for phase_2 postoperative-pain

Timeline
Completed

Started Aug 2021

Shorter than P25 for phase_2 postoperative-pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 15, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 20, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

August 7, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2022

Completed
Last Updated

August 13, 2021

Status Verified

August 1, 2021

Enrollment Period

6 months

First QC Date

January 15, 2021

Last Update Submit

August 7, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • The intensity of postoperative pain

    Assessed by the numerical rating pain scale (NRS)

    24 hours after surgery

Study Arms (2)

Group I

ACTIVE COMPARATOR

Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline.

Drug: USG-STAP with bupivacaine and dexmedetomidine

Group II

PLACEBO COMPARATOR

Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery

Drug: IP bupivacaine and dexmedetomidine

Interventions

Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline

Group I

Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery

Group II

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective LC under general anesthesia, aged from 20 to 65 years old.

You may not qualify if:

  • Contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis)
  • Altered conscious level
  • Pregnancy
  • Body mass index (BMI \> 35)
  • Patients who have difficulty understanding the study protocol 6- Patients who have any known contraindication to study medications 7- Patient refusal.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, 71515, Egypt

RECRUITING

Related Publications (1)

  • El Sabour AIA, Youssef HA, Ismail EA, Ahmed DH. Comparison of subcostal transversus abdominis block with intraperitoneal instillation of bupivacaine and dexmedetomidine for pain relief after laparoscopic cholecystectomy, randomized double blinded controlled study. BMC Anesthesiol. 2025 Nov 14;25(1):560. doi: 10.1186/s12871-025-03412-4.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

BupivacaineDexmedetomidine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Seham M Moeen, MD

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Seham M Moeen, MD

CONTACT

Dina H Ahmed, Msc

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assiut University

Study Record Dates

First Submitted

January 15, 2021

First Posted

January 20, 2021

Study Start

August 7, 2021

Primary Completion

February 15, 2022

Study Completion

February 15, 2022

Last Updated

August 13, 2021

Record last verified: 2021-08

Locations